quinazolines has been researched along with Inflammatory Response Syndrome, Systemic in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Azuma, J; Iekushi, K; Iwabayashi, M; Morishita, R; Rakugi, H; Sanada, F; Shimizu, K; Taniyama, Y | 1 |
Ozer, Z; Qazi, S; Tibbles, H; Uckun, FM; Vassilev, A | 1 |
2 other study(ies) available for quinazolines and Inflammatory Response Syndrome, Systemic
Article | Year |
---|---|
Hepatocyte growth factor inhibits lipopolysaccharide-induced oxidative stress via epithelial growth factor receptor degradation.
Topics: Animals; Aorta; Capillary Permeability; Cells, Cultured; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Hepatocyte Growth Factor; Humans; Inositol Polyphosphate 5-Phosphatases; Kidney; Lipopolysaccharides; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Oxidative Stress; Phosphoric Monoester Hydrolases; Protein Kinase Inhibitors; Quinazolines; Reactive Oxygen Species; RNA Interference; Systemic Inflammatory Response Syndrome; Transfection; Vascular Cell Adhesion Molecule-1 | 2012 |
Anti-inflammatory activity profile of JANEX-1 in preclinical animal models.
Topics: Acute Disease; Animals; Anti-Inflammatory Agents; Cell Line; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Hindlimb; Humans; Janus Kinase 3; Lipopolysaccharides; Macrophages; Mice; Nitric Oxide; Quinazolines; Signal Transduction; Systemic Inflammatory Response Syndrome; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha | 2008 |